Press Release
09.00 EEST / 08.00 CEST
"This strategic partnership with CBC represents a significant milestone in our ongoing effort to bring our cutting-edge nanotechnology to enable improved medicines for patients around the world.
Nanoform technology has been effective in several in vitro and in vivo studies across multiple routes of administration including oral, inhaled, ophthalmic and injectables, and across multiple molecule types such as enzalutamide and many other molecules.
The partnership commences immediately, and the companies have planned several joint activities to introduce their collaboration, including representation of Nanoform by CBC at CPHI Japan, which takes place at
For further information, please contact:
Albert Hæggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150
Christian.jones@nanoform.com
+44 (0)7804 474 771
hvh@nanoform.com
+46 (0)7686 650 11
Orientation Marketing
chris.halling@orientation.agency
+44 (0)7580 041 073
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
About CBC
CBC was founded in 1925 as a trading company dealing mainly in chemical products. As a "creative trading company" with a 100-year history, CBC has developed diverse businesses ranging from the fields of chemicals, resins, and pharmaceuticals to electronics, optical equipment, and agriscience with the aim of providing "health," "safety," and "convenience," which are indispensable for people to lead affluent lives. Recently, in addition to its trading company function, the company has been focusing on the manufacturer business, owning its own plants for manufacturing pharmaceutical intermediates, automobile parts, optical lenses, etc. The group's total sales, both domestic and international, are approximately
Nanoform Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended
https://news.cision.com/nanoform/r/nanoform-enters-exclusive-partnership-with-cbc-to-bring-best-in-class-nanomedicine-technology-to-jap,c3959747
https://mb.cision.com/Main/18905/3959747/2724309.pdf
(c) 2024 Cision. All rights reserved., source